Literature DB >> 2104228

Interleukin 2 produced by activated B lymphocytes acts as an autocrine proliferation-inducing lymphokine.

A Lagoo1, C K Tseng, S Sell.   

Abstract

Normal peripheral blood B cells produce a soluble factor after activation that is functionally indistinguishable from interleukin 2 (IL 2) and can support B cell proliferation in vitro. Purified rabbit peripheral blood B cells, when stimulated with a combination of ionomycin (0.5 microgram/mL) and phorbol myristate acetate (PMA) (1 ng/mL), secreted a soluble factor in the culture medium that supported the IL 2-dependent cell line CTLL-2. The ability of these supernatants to support CTLL-2 growth was almost completely blocked by rabbit antibodies against human recombinant IL 2 and by the anti-IL 2 receptor monoclonal antibody 7D4. These data strongly suggest that the growth factor secreted by rabbit B cells is IL 2. To examine the possibility that the IL 2 activity detected in the B-cell cultures may be derived from residual T cells, B cells were further purified by successive panning with a pan-T-cell monoclonal antibody, L11-135, and goat anti-rabbit IgG. These highly purified B cells produced levels of IL 2 activity comparable to those produced by the initial B cell populations. Comparison of IL 2 production by decreasing numbers of purified T cells and purified B cells also indicated that the B cells were the source of IL 2 activity. Supernatants of activated B cells could support proliferation of B-cell blasts, and this activity could be completely absorbed by CTLL-2 cells, indicating that IL 2 is a major growth factor for B cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104228     DOI: 10.1016/1043-4666(90)90028-r

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  2 in total

1.  Changes in bone mineral density, 25-hydroxyvitamin D3 and inflammatory factors in patients with hyperthyroidism.

Authors:  Yali Zhou; Xixia Wang; Maoyuan Xin; Haiting Zhuang
Journal:  Exp Ther Med       Date:  2021-04-14       Impact factor: 2.447

2.  Treatment of idiopathic CD4 T lymphocytopenia with IL-2.

Authors:  C Cunningham-Rundles; H W Murray; J P Smith
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.